Vivendy Therapeutics

About:

Vivendy Therapeutics is engaged in the development of enzyme replacement therapy.

Top Investors: EQT Life Sciences, TVM Capital, BioMedPartners, Aescap Venture

Description:

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Total Funding Amount:

$45.9M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2006-01-01

Contact Email:

info(AT)vivendy.ch

Founders:

Number of Employees:

11-50

Last Funding Date:

2008-06-23

IPO Status:

Private

Industries: